JDRF Canadian Clinical Trial Network (JDRF CCTN) is pleased to announce that Eli Lilly Canada Inc. has provided $120,000 in support of two CCTN Post-Doctoral Fellows for one year in the sum of $60,000 each.
JDRF is committed to facilitating the discovery and translation of promising targets or therapeutics to improve and restore glycemic control in people with type 1 Diabetes (T1D).
The NIDDK is pleased to share with you a list of newly issued Funding Opportunity Announcements (FOAs) that are soliciting research applications relevant to type 1 diabetes and its complications:
Helmsley’s Type 1 Diabetes Program has launched a Request for Proposals – the Future Technologies Initiative (FTI). The goal of the FTI is to incubate proof-of-concept, early-stage research and development in the following two tracks:
The goal of this Funding Opportunity Announcement (FOA) is to stimulate bioengineers, physiologists, bio-behavioral researchers, and designers in academic centers and small businesses to develop new approaches to create devices/components with enhanced accuracy and less patient burden that will represent real advancements regarding safety and effectiveness of glucose control technologies including open and closed loop hormone replacement systems.
This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications for funding to perform research leading to the development of novel and supportive technologies for the improvement of cell replacement interventions using novel biomaterials and devices for type 1 diabetes (T1D) treatment.
Dear Partners, Sponsors and Friends,
I would like to take the opportunity to thank you for collaborating with us to make the 2018 Diabetes Innovation Challenge the engine for innovative ideas and solutions that will change the quality of life for millions of people who are living with diabetes.
The Human Islet Research Network (HIRN) is announcing a competitive New Investigator Pilot Award. The goal of this award is to support a small number of new investigators of exceptional creativity who propose to apply bold and highly innovative new research approaches to biological problems under current investigation in HIRN.
JDRF is requesting applications for the following opportunity:
RESTORING PANCREATIC ALPHA CELL FUNCTION TO IMPROVE METABOLIC CONTROL IN TYPE 1 DIABETES
Purpose: The Catalyst Award in Diabetes, Endocrinology and Metabolic Diseases (Catalyst-DEMD) is designed to complement NIDDK's traditional, investigator-initiated grant programs by supporting individual scientists who propose pioneering and possibly transforming studies in DEMD topic areas.